Nkarta Announces Pricing of $240 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price.
